ClinicalTrials.Veeva

Menu

Lung Ultrasound in COVID-19 Patients (LUS-COVID)

A

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Status

Completed

Conditions

Covid19
ARDS
Ultrasound

Study type

Observational

Funder types

Other

Identifiers

NCT04487769
LUS-COVID

Details and patient eligibility

About

To assess the prognostic performance of an early global LUS score with respect to the mortality in ICU and duration of ventilation.

Full description

This is an international multicenter cohort study on data collected between March and April 2020. The first available lung ultrasound examination that used a 12-regions approach was used to calculate the global LUS score.

Patients are included if they fulfilled the following criteria: 1) admitted to one of the participating ICU; 2) for invasive ventilation; 3) for respiratory failure due to confirmed COVID-19; and 4) having had a LUS examination performed within the first week of start of invasive ventilation.

The primary and secondary outcomes were liberation from invasive ventilation and mortality.

Demographic, clinical and outcome variables will be presented as percentages for categorical variables and as medians with interquartile ranges (IQR) for continuous variables.

Receiver operating characteristics (ROC) analysis will be used to derive the prognostic discriminatory performance of global LUS score in determining succesful extubation and mortality at day 28. The Youden index will be used to derive the optimal cut-off. The association of global LUS with unfavourable outcomes are analyzed with Cox proportional hazard analysis (for successful extubation and alive at day 28), logistic regression models (mortality at day 28). Hazard ratio or odds ratio with 95% confidence intervals were calculated for each outcome.

Enrollment

137 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Admitted to an ICU participating in this study between February 1, 2020 and April 30, 2020
  • Confirmed with reverse transcriptase polymerase chain reaction (RT-PCR) COVID-19 infection
  • Having had received invasive ventilation
  • Having had examined at least once with lung ultrasound under invasive ventilation

Exclusion criteria

  • Age <18 years
  • First examination with LUS in patients already under extracorporeal membrane oxygenation (ECMO) support.

Trial contacts and locations

1

Loading...

Central trial contact

Luigi Pisani, MD; Charalampos Pierrakos, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems